Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E27.33 EPS (ttm)19.90 Insider Own19.40% Shs Outstand109.80M Perf Week-2.44%
Market Cap60.25B Forward P/E17.51 EPS next Y31.07 Insider Trans-3.74% Shs Float84.31M Perf Month-0.64%
Income2.28B PEG3.25 EPS next Q6.07 Inst Own69.90% Short Float2.22% Perf Quarter18.80%
Sales7.98B P/S7.55 EPS this Y-10.80% Inst Trans2.15% Short Ratio1.32 Perf Half Y50.84%
Book/sh110.50 P/B4.92 EPS next Y15.88% ROA15.80% Target Price531.50 Perf Year76.67%
Cash/sh36.14 P/C15.05 EPS next 5Y8.40% ROE21.00% 52W Range271.37 - 583.54 Perf YTD44.88%
Dividend- P/FCF35.33 EPS past 5Y44.00% ROI16.10% 52W High-6.77% Beta0.52
Dividend %- Quick Ratio3.70 Sales past 5Y22.80% Gross Margin89.70% 52W Low100.47% ATR22.49
Employees8100 Current Ratio4.20 Sales Q/Q33.20% Oper. Margin30.50% RSI (14)49.76 Volatility4.14% 3.52%
OptionableYes Debt/Eq0.06 EPS Q/Q35.90% Profit Margin28.60% Rel Volume4.33 Prev Close545.21
ShortableYes LT Debt/Eq0.06 EarningsMay 05 BMO Payout0.00% Avg Volume1.42M Price544.01
Recom2.20 SMA20-2.12% SMA503.85% SMA20039.20% Volume5,902,647 Change-0.22%
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Nov-12-19Initiated SunTrust Hold $360
Nov-07-19Upgrade Citigroup Neutral → Buy $340 → $420
Oct-17-19Resumed BofA/Merrill Neutral $325
Sep-23-19Upgrade Guggenheim Neutral → Buy $355 → $403
Aug-07-19Upgrade Robert W. Baird Neutral → Outperform $410
Jun-18-19Downgrade Argus Buy → Hold
May-23-19Resumed Citigroup Neutral
May-28-20 08:14AM  Dow Jones Futures Rise As Coronavirus Market Rally Rotation Continues; China OKs Hong Kong Security Law Investor's Business Daily
05:54AM  2 Top Healthcare Stocks to Buy Right Now Motley Fool
May-27-20 10:35AM  What Sanofi Might Buy With Its Regeneron Windfall Barrons.com
10:08AM  Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More Zacks
09:47AM  Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA Zacks
09:07AM  Morning Bell With Jim Cramer: Be Careful Buying Stocks TheStreet.com
06:27AM  Regeneron, Sanofi Get FDA Nod For Dupixent Treatment In Children SmarterAnalyst
05:16AM  Regeneron Announces Secondary Offering Pricing At $515/Share SmarterAnalyst
01:28AM  Drugmaker Sanofi to raise over $11 billion via sale of Regeneron shares Reuters
May-26-20 11:19PM  Sanofi sells half of its Regeneron stake for $6.1bn Financial Times
07:55PM  Regeneron Announces Pricing of Secondary Offering of its Common Stock Held by Sanofi PR Newswire
04:34PM  Global Stocks Rally on Recovery Hopes and Vaccine News Barrons.com
01:50PM  Sanofi to Sell Its 20.6% Stake in Regeneron, but Keep Their Collaboration Intact Motley Fool
12:06PM  Regeneron Is Finally Free of Sanofi. Why Thats Good for Its Stock. Barrons.com
11:39AM  FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis PR Newswire
10:41AM  Regeneron (REGN) to Buy Back Part of Its Stake Held by Sanofi Zacks
09:55AM  S&P 500, Dow Jones Today Top Resistance As Covid-19 Vaccine Race Heats Up Investor's Business Daily
09:03AM  Sanofi to Sell Stake in Regeneron, Existing Deal Unchanged Zacks
08:44AM  Regeneron to buy back $5 billion in stock as Sanofi sells part of its stake MarketWatch
07:54AM  Sanofi shares down despite $13 billion Regeneron payday Reuters
06:54AM  Sanofi Selling Long-Standing Stake in Regeneron for $13 Billion TheStreet.com
06:48AM  Sanofi Adds Firepower in Exiting $13 Billion Regeneron Stake Bloomberg
02:49AM  Regeneron and Sanofis Dupixent Shows Positive Trial Data, Meets Co-Primary Endpoints SmarterAnalyst
May-25-20 10:04PM  Sanofi/Regeneron: lockdown dispels a lock-up Financial Times
03:05PM  Regeneron To Repurchase $5 Billion Stake From Sanofi SmarterAnalyst
01:20PM  U.S.' Regeneron to buy back $5 billion stake held by Sanofi Reuters
12:40PM  Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase PR Newswire
03:26AM  Sanofi to slash $12bn stake in US biotech Regeneron Financial Times
May-24-20 02:40PM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-22-20 06:47PM  Dupixent® (dupilumab) Eosinophilic Esophagitis Trial Meets Both Co-Primary Endpoints PR Newswire
01:09PM  Edited Transcript of REGN earnings conference call or presentation 5-May-20 12:30pm GMT Thomson Reuters StreetEvents
May-21-20 03:48PM  Fmr. CDC Official: 'were not cutting any corners' on COVID-19 vaccine development Yahoo Finance Video
02:49PM  Top Health Care Stocks for June 2020 Investopedia
May-19-20 08:03AM  5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up Zacks
May-18-20 05:28PM  Stocks Amid COVID-19 Outbreak: Winners So Far in the Health Industry Insider Monkey
May-15-20 03:43PM  Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis Zacks
01:23PM  3 Earnings Stocks to Buy While They Climb Above Everything Else InvestorPlace
11:20AM  Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners Zacks
May-14-20 01:46PM  Zacks.com featured highlights include: SpartanNash, BG Foods, Regeneron, Vipshop and United Therapeutics Zacks
01:27PM  Pluralsight, Stanley Black Decker, Gilead, Regeneron and GlaxoSmithKline as Zacks Bull and Bear of the Day Zacks
11:51AM  Coronavirus Vaccine Progress Accelerates Yahoo Finance
11:16AM  Relaxing the Lockdown: Move Slowly, Stay Nimble Yahoo Finance
May-13-20 10:32AM  Regeneron Pharmaceuticals Sets Up Again Investor's Business Daily Video
08:16AM  Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners Zacks
May-12-20 07:52AM  This unlikely stock is the biggest winner since the February stock market top MarketWatch
May-11-20 11:13PM  JPMorgan Genetic-Therapies Fund Finds Success in Covid-19 Era Bloomberg
07:00AM  Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration PR Newswire
06:34AM  RPT-BUZZ-U.S. stocks weekly: Silver lining Reuters
May-10-20 02:02PM  Better Coronavirus Stock: Inovio Pharmaceuticals or Regeneron? Motley Fool
May-09-20 02:19PM  The Nasdaq is now up for the year here are the indexs best-performing stocks MarketWatch
May-08-20 06:16PM  Translate Bio Boosted by Sanofi Vaccine Agreement GuruFocus.com
04:53PM  This PayPal Options Move Is Better Than Cash Barrons.com
02:46PM  Government to test remdesivir with Lilly drug in COVID-19 patients MarketWatch
09:25AM  6 Stocks to Buy and Hold (And 6 Picks to Avoid) Kiplinger
May-07-20 09:59AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi Zacks
09:41AM  The Nasdaq just wiped out all of its losses for 2020--a stunning feat in the aftermath of the coronvirus crisis MarketWatch
May-06-20 05:18PM  U.S. Cases Rise 1.9% Again, Below Weeks Average: Virus Update Bloomberg
12:55PM  Regeneron Pharmaceuticals Could Trade Sideways Before Renewed Gains TheStreet.com
09:10AM  Stock Market News for May 6, 2020 Zacks
May-05-20 11:31PM  Regeneron Pharmaceuticals (REGN) Q1 2020 Earnings Call Transcript Motley Fool +6.01%
04:21PM  Wayfair (W) Celebrates Cinco de Mayo with Big Q1 Beat (revised) Zacks
04:18PM  US STOCKS-Wall Street rises as lockdowns ease, healthcare shares jump Reuters
04:11PM  Small Biotech Rockets To 5-Year High On Regeneron-Rivaling Gene Therapy Investor's Business Daily
04:11PM  Regeneron Jumps On Quarterly Beat, Plans Coronavirus Drug Study In June Investor's Business Daily
04:02PM  US STOCKS-Wall Street rises as lockdowns ease, healthcare shares jump Reuters
03:31PM  Regeneron to Begin Human Studies of Covid-19 Treatment in June TheStreet.com
03:22PM  Regeneron Says Its COVID-19 Combo Treatment Could Be Ready for People This Fall Motley Fool
02:44PM  Regeneron Posts Rapid Growth Due to Dupixent Motley Fool
02:31PM  US STOCKS-Wall Street jumps as healthcare shares rise, lockdowns ease Reuters
01:15PM  US STOCKS-Wall Street jumps as energy shares rise, lockdowns ease Reuters
10:22AM  Wayfair (W) Celebrates Cinco de Mayo with Big Q1 Beat Zacks
09:59AM  Dow Jones Today, Stocks Climb On Earnings, Reopenings, Oil Prices; Covid Stocks Rally: Chegg Nails Breakaway Gap Investor's Business Daily
09:37AM  Q1 Earnings and Economic Data Deluge Zacks
09:08AM  Regeneron's (REGN) Q1 Earnings & Sales Surpass Estimates Zacks
08:08AM  Dow Jones Futures Jump On Easing Lockdowns; Apple, Microsoft In Buy Range In Current Stock Market Rally Investor's Business Daily
08:00AM  The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout Benzinga
07:36AM  Regeneron says COVID-19 antibody cocktail may be available by fall Reuters
06:44AM  Regeneron earnings beat expectations, plans to begin human studies of COVID-19 treatment in June MarketWatch
06:40AM  Regeneron quarterly profit jumps 35% on higher demand for eye drug Eylea Reuters
12:59AM  Libtayo® (cemiplimab) Shows Clinically-Meaningful and Durable Responses in Second-line Advanced Basal Cell Carcinoma PR Newswire
May-04-20 09:13AM  11 Earnings Reports to Watch This Week TheStreet.com
May-01-20 03:58PM  How Gilead's coronavirus drug breakthrough is setting the tone for other potential treatments Yahoo Finance
Apr-30-20 05:31PM  Amgen Stock Jumps on Earnings, Covid-19 Trial Announcement Barrons.com
02:21PM  Genius Hedge Fund Manager Is Crazy About This Stock Insider Monkey
10:53AM  Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings? Zacks
10:47AM  25 Blue Chips With Brawny Balance Sheets Kiplinger
08:51AM  Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat Zacks
Apr-29-20 05:45PM  Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know Zacks
05:05PM  Dow Jones Rips 1,746 Points Higher In 6 Days As Fed Pledges Asset Buys; Vertex Up After Hours Investor's Business Daily
06:08AM  COVID-19 treatment yields disappointing data in trial and shows its not easy to develop drugs MarketWatch
Apr-28-20 03:04PM  Coronavirus update: German infection rate ticks higher after reopening moves, offers lesson to U.S. governors MarketWatch
12:33PM  Regeneron (REGN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
11:46AM  Polen Capital is Bullish on Regeneron Pharmaceuticals (REGN) and MSCI (MSCI) Insider Monkey
11:36AM  Regeneron Stock Has Hit Its Peak, Says Citi Barrons.com
11:21AM  Stocks Gains Have Faded Away Barrons.com
10:35AM  First-Mover Pandemic Disease Fight ETF On The Way Zacks
07:50AM  Here are the not-too-pricey stocks Goldman recommends as economies emerge from coronavirus shutdowns MarketWatch
12:49AM  PRESS DIGEST- New York Times business news - April 28 Reuters
Apr-27-20 05:52PM  The Latest Updates on 9 Experimental Coronavirus Treatments Barrons.com
04:19PM  Covid Report: Arthritis Drug Tested As Coronavirus Treatment For Critically Ill Investor's Business Daily
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services for the development of new treatments combating the coronavirus. It also has a strategic collaboration with Zai Lab Limited. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VAGELOS P ROYChairman of the BoardMay 21Sale577.49783452,178307,749May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 21Sale564.37148,81183,984,786308,532May 22 06:21 PM
VAGELOS P ROYChairman of the BoardMay 20Option Exercise30.63312,5009,571,875497,063May 22 06:21 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 15Sale572.008,3804,793,36014,438May 15 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretMay 14Option Exercise59.2018,3111,084,01132,749May 15 04:03 PM
SING GEORGE LDirectorMay 13Option Exercise33.425,000167,100120,415May 13 09:00 PM
SING GEORGE LDirectorMay 13Sale580.005,0002,900,000115,415May 13 09:00 PM
SCHLEIFER LEONARD SPresident & CEOMay 12Sale569.22150,92285,908,042474,499May 13 09:01 PM
SCHLEIFER LEONARD SPresident & CEOMay 11Option Exercise30.63312,5009,571,875722,368May 13 09:01 PM
SING GEORGE LDirectorMay 11Sale575.00850488,7502,150May 13 09:00 PM
STAHL NEILEVP Research and DevelopmentMay 11Sale569.525,3053,021,28911,380May 11 04:39 PM
STAHL NEILEVP Research and DevelopmentMay 08Option Exercise52.0312,500650,37523,880May 11 04:39 PM
Zoghbi Huda YDirectorMay 07Option Exercise391.925,1182,005,8475,761May 08 04:03 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 07Sale564.3239,58322,337,30628,251May 08 04:04 PM
Zoghbi Huda YDirectorMay 07Sale566.525,1182,899,461643May 08 04:03 PM
BROWN MICHAEL SDirectorMay 07Sale562.001,8091,016,658643May 07 04:14 PM
BROWN MICHAEL SDirectorMay 06Option Exercise371.985,4702,034,7395,863May 07 04:14 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise177.8215,0002,667,30016,830May 08 04:03 PM
RYAN ARTHUR FDirectorMay 06Option Exercise373.6750,12418,729,67078,967May 07 06:22 PM
Van Plew Daniel PEVP & General Mgr Industrial OMay 06Option Exercise52.0385,5794,452,67596,051May 08 04:04 PM
RYAN ARTHUR FDirectorMay 06Sale550.8850,12427,612,50928,843May 07 06:22 PM
GOLDSTEIN JOSEPH LDirectorMay 06Sale560.002,0001,120,0007,643May 06 04:19 PM
Tessier-Lavigne MarcDirectorMay 06Sale563.9715,0008,459,4961,830May 08 04:03 PM
RYAN ARTHUR FDirectorMay 01Sale520.3710052,03728,843May 04 04:02 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale570.301,7781,013,98514,438Apr 20 07:27 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 20Sale565.483,5221,991,61116,216Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 20Sale566.943,2501,842,53924,373Apr 20 07:29 PM
Landry Robert EEVP Finance CFOApr 17Option Exercise272.7012,5003,408,75036,873Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Option Exercise59.2011,622688,02222,458Apr 20 07:26 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 17Sale557.382,2671,263,58614,438Apr 20 07:26 PM
Landry Robert EEVP Finance CFOApr 17Sale557.68991552,66124,373Apr 20 07:29 PM
Landry Robert EEVP Finance CFOApr 16Option Exercise272.704,0001,090,80028,373Apr 20 07:29 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 16Option Exercise59.205,000296,00019,438Apr 20 07:26 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 15Sale518.212,2621,172,18714,438Apr 16 04:04 PM
Landry Robert EEVP Finance CFOApr 15Sale518.49853442,27624,373Apr 16 04:03 PM
Landry Robert EEVP Finance CFOApr 14Option Exercise272.703,500954,45027,873Apr 16 04:03 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 14Option Exercise59.205,000296,00019,438Apr 16 04:04 PM
STAHL NEILEVP Research and DevelopmentApr 14Sale521.075,4972,864,30711,380Apr 15 04:17 PM
STAHL NEILEVP Research and DevelopmentApr 13Option Exercise52.0313,079680,50024,459Apr 15 04:17 PM
Landry Robert EEVP Finance CFOApr 13Sale509.79828422,10824,373Apr 13 07:23 PM
Landry Robert EEVP Finance CFOApr 09Option Exercise272.703,500954,45027,873Apr 13 07:23 PM
Landry Robert EEVP Finance CFOApr 07Sale497.52696346,27124,373Apr 08 04:02 PM
Landry Robert EEVP Finance CFOApr 06Option Exercise272.703,000818,10027,373Apr 08 04:02 PM
Landry Robert EEVP Finance CFOApr 03Sale494.28683337,59224,373Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Option Exercise272.703,000818,10028,726Apr 03 04:49 PM
Landry Robert EEVP Finance CFOApr 02Sale495.8810552,06825,056Apr 03 04:50 PM
Landry Robert EEVP Finance CFOApr 02Sale489.321,248610,67225,161Apr 03 04:49 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 02Sale489.986,7973,330,40614,438Apr 03 04:08 PM
Fenimore Christopher R.VP ControllerApr 01Option Exercise30.631,20036,75614,297Apr 03 04:05 PM
LAROSA JOSEPH JEVP General Counsel and SecretApr 01Option Exercise59.2015,000888,00023,924Apr 03 04:08 PM
Landry Robert EEVP Finance CFOApr 01Option Exercise272.706,0001,636,20026,937Apr 03 04:49 PM
Landry Robert EEVP Finance CFOApr 01Sale488.02600292,81124,373Apr 03 04:49 PM
Fenimore Christopher R.VP ControllerApr 01Sale488.411,200586,09613,097Apr 03 04:05 PM
RYAN ARTHUR FDirectorApr 01Sale483.8510048,38528,943Apr 01 06:49 PM
RYAN ARTHUR FDirectorMar 30Sale466.6910046,66929,043Apr 01 06:49 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 10Sale470.47117,81555,428,041517,799Mar 11 04:05 PM
YANCOPOULOS GEORGEPresident and Chief ScientificMar 09Option Exercise30.63246,7367,557,524713,990Mar 11 04:05 PM
GOLDSTEIN JOSEPH LDirectorMar 09Option Exercise33.422,00066,84011,643Mar 10 04:05 PM
GOLDSTEIN JOSEPH LDirectorMar 09Sale475.842,000951,6849,643Mar 10 04:05 PM
STAHL NEILEVP Research and DevelopmentFeb 27Sale452.2610,3494,680,46011,380Feb 28 04:40 PM
SING GEORGE LDirectorFeb 26Option Exercise33.422,50083,550117,915Feb 28 04:30 PM
STAHL NEILEVP Research and DevelopmentFeb 26Option Exercise52.0325,0001,300,75036,380Feb 28 04:40 PM
SING GEORGE LDirectorFeb 26Sale452.832,4001,086,8002,400Feb 28 04:30 PM
SING GEORGE LDirectorFeb 26Sale460.002,5001,150,000115,415Feb 28 04:30 PM
Landry Robert EEVP Finance CFOFeb 26Sale456.2120091,24224,973Feb 26 06:14 PM
Van Plew Daniel PEVP & General Mgr Industrial OFeb 26Sale457.2315,6427,152,01628,251Feb 27 04:12 PM
Van Plew Daniel PEVP & General Mgr Industrial OFeb 25Option Exercise30.6332,7351,002,67360,986Feb 27 04:12 PM
Landry Robert EEVP Finance CFOFeb 25Option Exercise272.701,000272,70026,187Feb 26 06:14 PM
Landry Robert EEVP Finance CFOFeb 25Sale449.0121496,08825,173Feb 26 06:14 PM
Landry Robert EEVP Finance CFOFeb 24Option Exercise272.701,000272,70025,973Feb 26 06:14 PM
BROWN MICHAEL SDirectorFeb 24Option Exercise273.672,000547,3402,643Feb 25 04:03 PM
BROWN MICHAEL SDirectorFeb 24Sale419.002,000838,001643Feb 25 04:03 PM
YANCOPOULOS GEORGEPresident and Chief ScientificFeb 24Sale420.17118,12349,631,741517,799Feb 25 04:05 PM
Tessier-Lavigne MarcDirectorFeb 13Option Exercise53.0814,279757,94411,109Feb 14 04:10 PM
Tessier-Lavigne MarcDirectorFeb 13Sale400.0114,2795,711,7111,830Feb 14 04:10 PM
Landry Robert EEVP Finance CFOFeb 13Sale400.0510742,80624,973Feb 14 04:10 PM
Landry Robert EEVP Finance CFOFeb 12Option Exercise272.70500136,35025,473Feb 14 04:10 PM
GOLDSTEIN JOSEPH LDirectorFeb 07Sale382.831,000382,8309,643Feb 10 04:45 PM
MURPHY ANDREW JEVP ResearchJan 27Sale340.918,0002,727,27949,951Jan 28 05:06 PM
Fenimore Christopher R.VP ControllerJan 24Option Exercise30.6350015,31513,097Jan 27 04:04 PM
SING GEORGE LDirectorJan 02Option Exercise24.4115,000366,150130,095Jan 06 04:02 PM
SING GEORGE LDirectorJan 02Sale371.9815,0005,579,700115,095Jan 06 04:02 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise30.6340012,25212,597Dec 23 04:02 PM
BROWN MICHAEL SDirectorDec 13Option Exercise273.674,0001,094,6804,323Dec 13 04:07 PM
Fenimore Christopher R.VP ControllerDec 13Sale376.141,682632,66512,197Dec 13 06:03 PM
BROWN MICHAEL SDirectorDec 13Sale373.994,0001,495,968323Dec 13 04:07 PM
VAGELOS P ROYChairman of the BoardDec 13Sale376.0451,84219,494,489304,485Dec 13 05:43 PM
SCHLEIFER LEONARD SPresident & CEODec 12Option Exercise21.25312,4006,638,500571,708Dec 13 04:05 PM
VAGELOS P ROYChairman of the BoardDec 12Option Exercise21.25107,6552,287,669412,140Dec 13 05:43 PM
YANCOPOULOS GEORGEPresident and CSODec 12Option Exercise21.25245,2955,212,519521,876Dec 13 04:44 PM
Fenimore Christopher R.VP ControllerDec 12Option Exercise52.033,100161,29315,297Dec 13 06:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Option Exercise33.421,00033,42011,323Dec 02 04:03 PM
GOLDSTEIN JOSEPH LDirectorNov 27Sale370.001,000370,00010,323Dec 02 04:03 PM
STAHL NEILEVP Research and DevelopmentNov 26Sale364.074,0061,458,46722,455Nov 26 04:29 PM
STAHL NEILEVP Research and DevelopmentNov 25Option Exercise52.0310,000520,30032,455Nov 26 04:29 PM
VAGELOS P ROYChairman of the BoardNov 25Sale363.8722,1498,059,412304,485Nov 26 04:02 PM
VAGELOS P ROYChairman of the BoardNov 22Option Exercise21.2546,138980,433386,716Nov 26 04:02 PM
GOLDSTEIN JOSEPH LDirectorNov 22Option Exercise33.421,00033,42011,323Nov 22 04:07 PM
GOLDSTEIN JOSEPH LDirectorNov 22Sale360.001,000360,00010,323Nov 22 04:07 PM
GOLDSTEIN JOSEPH LDirectorNov 21Option Exercise33.421,00033,42011,323Nov 22 04:07 PM